![\"Oppr.ai](\"https:\/\/www.innovationquarter.nl\/en\/wp-content\/uploads\/sites\/2\/2026\/05\/oppr-ai-receives-an-investment-from-uniiq-1024x683.jpg\")
<\/figure>\n\n\n\n\u201cThis seed capital allows us to further develop our digital operator and accelerate adoption, making European manufacturing smarter, more efficient and more sustainable.\u201d<\/em> \u2013\u00a0Floris Wyers<\/a>, Founder & CEO of Oppr.ai<\/p>\n\n\n\n UNIIQ provides not only funding, but also access to a valuable network of tech-driven companies and strategic expertise to support focused growth. In earlier pilots, Oppr.ai\u2019s technology already led to reduced product rejection and less unplanned downtime. <\/p>\n\n\n\n Oppr.ai has already demonstrated in multiple pilots how its platform supports manufacturing companies by combining the objective \u201cwhat\u201d from machine data with the crucial \u201cwhy\u201d from human observations. This gives companies a complete, real-time view of their operations, revealing deep insights that previously remained hidden. <\/p>\n\n\n\n StemX Bio<\/a>\u00a0creates human 3D micro-tissues that mimic diseases more accurately than animal models. This speeds up the development of safe and effective medicines, reduces reliance on animal testing and lowers the costs of drug development. With UNIIQ\u2019s investment, the company will scale up its validated pancreatic tissue model, automate production and begin developing a new thyroid model \u2013 expanding its pipeline and entering new markets.\u00a0<\/p>\n\n\n\n \u201cWith this pre-seed financing, we can bring our innovative platform to market and expand our team. It is the crucial step to serve our first customers and to set a new standard for the development of better medicines.\u201d <\/em>\u2013\u00a0Jane Spirkoski<\/a>, CEO of StemX Bio<\/p>\n\n\n\n Beyond funding, StemX Bio benefits from UNIIQ\u2019s network in biotech and life sciences, helping the company attract talent, build partnerships and prepare for future investment rounds. <\/p>\n\n\n\n The startup already has a fully operational lab and holds an exclusive IP license from LUMC. It also secured Letters of Intent from a global leader in drug research and two top academic labs. These milestones helped StemX Bio successfully close its pre-seed round, with funding from UNIIQ and LEH, supplemented by prestigious grants such as the MIT Feasibility grant and a Proefdiervrij voucher.<\/p>\n\n\n\n UNIIQ is a \u20ac50 million proof-of-concept fund that helps entrepreneurs in Zuid-Holland bring unique innovations to market. The fund provides academic spin-offs and innovative startups with the seed capital and strategic coaching needed to bridge the riskiest phase \u2014 from concept to promising company. Over 60% of UNIIQ-backed startups have already secured follow-on funding, collectively raising over \u20ac275 million. UNIIQ is made possible by Erasmus MC, TU Delft, Leiden University, Erasmus University, InnovationQuarter, the European Union, the Province of Zuid-Holland, the Ministry of Economic Affairs and Climate Policy, the Netherlands Enterprise Agency (RVO), TNO, and the municipalities of Rotterdam, The Hague, and Leiden. InnovationQuarter acts as the fund manager of UNIIQ. <\/p>\n\n\n\n Curious which investment fund can help grow your idea?\u00a0<\/strong><\/p>\n\n\n\n\t\t\t\t\t\t\n\t\t\t \n\t\t\t\t\t\t\tFind out which fund fits your growth\n\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t\tIn just 5 minutes\n\t\t\t\t\t<\/p>\n\t\t\t\t<\/div>\n\n\t\t\t\tStemX Bio: human micro-tissues as an alternative to animal testing\u00a0<\/h2>\n\n\n\n
![\"stemxbio-receives-an-investment-from-uniiq\"](\"https:\/\/www.innovationquarter.nl\/en\/wp-content\/uploads\/sites\/2\/2026\/05\/stemxbio-receives-an-investment-from-uniiq-1024x683.jpg\")
<\/figure>\n\n\n\nAbout UNIIQ\u00a0<\/h3>\n\n\n\n
Quickscan<\/h2>\n\t\t\t\t